Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Alcon (SWX:ALC) shares are in focus after the company agreed a non exclusive collaboration with RxSight to co develop adjustable presbyopia correcting intraocular lenses for cataract patients seeking more tailored visual outcomes.
See our latest analysis for Alcon.
At a share price of CHF54.0, Alcon has seen short term share price support, with a 1 month share price return of 1.39%, but the 90 day share price return is down 11.48% and the 1 year total shareholder return is down 20.92%. This points to weaker momentum despite product news such as the RxSight collaboration.
If this kind of specialist eye care theme interests you, it can be helpful to compare Alcon with other healthcare companies using AI by scanning our 131 healthcare AI stocks
Alcon now trades at CHF54.0 while consensus and intrinsic value estimates sit much higher, leaving a wide gap. Is the recent weakness a sign the stock deserves a discount, or does it point to mispriced potential ahead of a valuation check?
Most Popular Narrative: 29.5% Undervalued
Alcon is trading at CHF54.0 against a narrative fair value of CHF76.62, so the current pricing sits well below those long term assumptions.
Accelerated new product launches including Unity VCS (next gen surgical platform), PanOptix Pro (premium IOL), Tryptyr (first in class dry eye Rx), Precision7 (novel contact lens), and recent pipeline accretive M&A (STAAR, LumiThera, Voyager) provide significant near and medium term opportunities for share gain, mix improvement, and new market entry, underpinning upside to both revenue and net margins as these innovations scale.
Want to see what kind of revenue lift and margin profile that product pipeline is built around? The narrative leans on compounding top line growth, rising profitability and a rich earnings multiple that still assumes investors stay confident in the story.
Result: Fair Value of CHF76.62 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to factor in competitive pressure in intraocular lenses, as well as ongoing tariff, legal and acquisition integration costs that could limit the Alcon upside story.
Find out about the key risks to this Alcon narrative.
Another View: What Multiples Say About Alcon
That 29.5% undervaluation signal for Alcon sits uncomfortably beside its current P/E of 39.8x, which is higher than both the European Medical Equipment industry at 26.8x and the peer average of 26.5x, as well as our fair ratio of 37.2x.
This gap suggests investors are already paying a premium multiple for Alcon despite recent share price weakness. The key question is whether earnings progress can justify that richer P/E, or if the market could drift back toward the fair ratio over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Alcon's valuation and outlook, this may be an appropriate moment to review the full picture yourself and weigh both sides carefully using the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Alcon?
If you stop at Alcon, you could miss out on other compelling setups. Put the Simply Wall St screener to work to widen your opportunity set.
-
Target potential value opportunities early by scanning companies that currently screen as 216 high quality undervalued stocks before the crowd pays attention.
-
Prioritise resilience by focusing on businesses in the 296 resilient stocks with low risk scores that combine lower risk scores with steadier profiles.
-
Spot future standouts by reviewing the screener containing 499 high quality undiscovered gems that pair strong fundamentals with relatively low market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALC.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
